• Lakefront Biotherapeutics launched a share repurchase program of up to EUR 50 million.
• Buybacks can run through Dec. 31, 2026; Morgan Stanley will execute purchases in the open market.
• Repurchased ordinary shares will be held as treasury shares; the company can suspend or end the program at any time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606091601PRIMZONEFULLFEED1001186812) on June 09, 2026, and is solely responsible for the information contained therein.